Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDEyeGate Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
EyeGate Pharmaceuticals, Inc. Earnings Date And Information
EyeGate Pharmaceuticals, Inc. last posted its earnings results on Monday, November 8th, 2021. The company reported $-0.42007 earnings per share for the quarter, missing analysts' consensus estimates of $-0.34 by $0.08007. The company had revenue of 0 for the quarter and had revenue of 12,059 for the year. EyeGate Pharmaceuticals, Inc. has generated $-3 earnings per share over the last year ($-2.54 diluted earnings per share) and currently has a price-to-earnings ratio of -26.37. EyeGate Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 8th, 2021 based on prior year's report dates.
EyeGate Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/08/2024 | Q3 2024 | N/A | -$0.81 | N/A | N/A | $0 |
| 08/09/2024 | Q2 2024 | N/A | -$0.53 | N/A | N/A | $20,000 |
| 11/15/2021 | Q3 2021 | N/A | -$0.42 | N/A | N/A | $0 |
| 08/12/2021 | Q2 2021 | -$0.42 | -$0.35 | 0.07 | N/A | $0 |
| 05/12/2021 | Q1 2021 | -$0.38 | -$0.37 | 0.01 | N/A | $0 |
| 03/25/2021 | Q4 2020 | -$0.44 | -$0.53 | -0.09 | N/A | $12,059 |
| 11/09/2020 | Q3 2020 | -$0.42 | -$0.44 | -0.02 | N/A | $0 |
| 08/06/2020 | Q2 2020 | -$0.43 | -$0.38 | 0.05 | N/A | $0 |
| 05/06/2020 | Q1 2020 | N/A | -$0.43 | N/A | N/A | $0 |
| 03/04/2020 | Q4 2019 | -$0.81 | -$0.91 | -0.1 | N/A | $0 |
| 11/07/2019 | Q3 2019 | N/A | -$1.15 | N/A | N/A | $0 |
| 08/08/2019 | Q2 2019 | -$0.75 | -$0.63 | 0.12 | N/A | $0 |
| 05/08/2019 | Q1 2019 | -$0.75 | $0.30 | 1.05 | N/A | $2.69 M |
| 03/01/2019 | Q4 2018 | -$0.90 | -$0.88 | 0.02 | N/A | $0 |
| 11/13/2018 | Q3 2018 | -$1.20 | -$1.08 | 0.12 | N/A | $314,500 |
| 08/03/2018 | Q2 2018 | -$2.10 | -$1.11 | 0.99 | N/A | $242,012 |
| 05/11/2018 | Q1 2018 | -$3.60 | -$2.07 | 1.53 | N/A | $1.10 M |
| 03/02/2018 | Q4 2017 | -$3.60 | -$2.47 | 1.13 | N/A | $0 |
| 11/14/2017 | Q3 2017 | -$3.22 | -$3.61 | -0.39 | N/A | $74,696 |
| 08/04/2017 | Q2 2017 | -$0.20 | -$4.14 | -3.94 | N/A | $148,290 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
EyeGate Pharmaceuticals, Inc. Earnings: FAQ's
EyeGate Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 8th, 2021 based offlast year's report dates.
The conference call for EyeGate Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for EyeGate Pharmaceuticals, Inc.'s latest earnings report can be read online.
EyeGate Pharmaceuticals, Inc. (:EYEG) has a recorded annual revenue of $12,059.
EyeGate Pharmaceuticals, Inc. (:EYEG) has a recorded net income of $-8,091,940.EyeGate Pharmaceuticals, Inc. has generated $-2.54 earnings per share over the last four quarters.
EyeGate Pharmaceuticals, Inc. (:EYEG) has a price-to-earnings ratio of -26.37 and price/earnings-to-growth ratio is 0.17.